Skip to main content
Clinical Trials/NCT01207674
NCT01207674
Completed
Not Applicable

Transversal Multiaxial Evaluation and 5-year Follow-up of a Cohort of French Gamblers.

Nantes University Hospital7 sites in 1 country641 target enrollmentApril 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pathological or "at Risk" Gambling
Sponsor
Nantes University Hospital
Enrollment
641
Locations
7
Primary Endpoint
Number of psychiatric comorbidities
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This study is divided into two stages. The first stage is a transversal study and corresponds to the recruitment of participants, which will last about two years. Three groups of gamblers will be constituted : Non-problematic gamblers (NPG), Problematic gamblers Not in Care (PGNC) and Problematic gamblers in Care (PGC).The second stage is a prospective 5-year follow-up study of the cohort (only the initial NPG and PGNC groups are concerned by the follow-up study), that consists on an annual follow-up evaluation. The main objective of the first stage of the study is to compare the characteristics of the three groups of gamblers on some socio-demographic and clinical data. These comparisons will allow us to identify, among all data, those that will be most likely to explain the evolution of the practice of gambling (appearance or resolution of a gambling problem), and recourse to specific care. These such isolated data will be tested in the second stage of the study, in order to determine those that are predictive factors of three steps of the gambling course of some gamblers : evolution of a controlled gambling practice into a problematic gambling practice, resolution of the problematic gambling practice without intervention of care, and first recourse to specific care.

Registry
clinicaltrials.gov
Start Date
April 2009
End Date
September 2016
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • To be 18 to 65 years old
  • To have gambled during the last year
  • To gamble at least one time a year

Exclusion Criteria

  • To be under tutelage (a French protecting measure for persons with altered judgement)
  • To present obvious cognitive disturbances
  • To have difficulties to read and/or write in French language

Outcomes

Primary Outcomes

Number of psychiatric comorbidities

Time Frame: 5 years

The 10 psychiatric comorbidities explored by the MINI are major depressive episode, (hypo)-maniac episode, 5 anxiety disorders (panic disorder ± agoraphobia, social phobia, obsessional-compulsive disorder, PTSD, generalised anxiety disorder), substance use disorders (alcohol, other psychoactive substances), psychotic disorders, and eating disorders (anorexia nervosa and bulimia).

Secondary Outcomes

  • Clinical data(5 years)
  • Socio-demographic data(5 years)

Study Sites (7)

Loading locations...

Similar Trials

Unknown
Not Applicable
The Efficacy and Safety of Electronic Cigarettes: a 5-year Follow-up StudyCardiovascular DiseasesChronic Obstructive Pulmonary DiseasesCancer of the LungCancer of the BladderCancer of the Stomach
NCT01785537Università degli Studi 'G. d'Annunzio' Chieti e Pescara1,050
Recruiting
Not Applicable
A multi-center, cross-section, retrospectivestudy of TCM symptome characteristics of atherosclerotic myocardial infarctioAtherosclerotic myocardial infarction
ITMCTR2200005906Zhejiang Chinese Medical University
Active, not recruiting
Not Applicable
A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10 mg daily doses of GW501516 in subjects with low HDLc
EUCTR2004-000882-36-FIGlaxoSmithKine Research & Development Limited424
Active, not recruiting
Not Applicable
A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10 mg daily doses of GW501516 in subjects with low HDLcTreatment of dyslipidaemia
EUCTR2004-000882-36-SEGlaxoSmithKine Research & Development Limited424
Active, not recruiting
Not Applicable
A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10 mg daily doses of GW501516 in subjects with low HDLcTreatment of dyslipidaemia
EUCTR2004-000882-36-DKGlaxoSmithKine Research & Development Limited424